Page 34 - JCTR-11-4

Journal of Clinical and
Translational Research Propranolol as a treatment for HCC

Beta blockers: An innovation in the treatment of infantile infection. J Hepatol. 2017;67(2):370-398.
hemangiomas. J Clin Aesthet Dermatol. 2014;7(7):37-45.
doi: 10.1016/j.jhep.2017.03.021
46. Musumeci M, Maccari S, Sestili P, et al. Propranolol enhances 57. Papatheodoridis GV, Chan HLY, Hansen BE, Janssen HL,
cell cycle-related gene expression in pressure overloaded Lampertico P. Risk of hepatocellular carcinoma in chronic
hearts. Br J Pharmacol. 2011;164(8):1917-1928.
hepatitis B: Assessment and modification with current
doi: 10.1111/j.1476-5381.2011.01504.x antiviral therapy. J Hepatol. 2015;62(4):956-67.
47. Björkström NK, Strunz B, Ljunggren HG. Natural killer cells doi: 10.1016/j.jhep.2015.01.002
in antiviral immunity. Nat Rev Immunol. 2022;22(2):112-123.
58. Ren H, Huang Y. Effects of pegylated interferon‐α based
doi: 10.1038/s41577-021-00558-3 therapies on functional cure and the risk of hepatocellular
carcinoma development in patients with chronic hepatitis B.
48. Lin Y, Liu Y, Gao Z, et al. Beta-adrenergic receptor blocker
propranolol triggers anti-tumor immunity and enhances J Viral Hepat. 2019;26:5-31.
irinotecan therapy in mice colorectal cancer. Eur J doi: 10.1111/jvh.13150
Pharmacol. 2023;949:175718.
59. Pawlotsky JM. New hepatitis C therapies: The
doi: 10.1016/j.ejphar.2023.175718 toolbox, strategies, and challenges. Gastroenterology.
2014;146(5):1176-1192.
49. Rousalova I, Krepela E. Granzyme B-induced apoptosis
in cancer cells and its regulation (review). Int J Oncol. doi: 10.1053/j.gastro.2014.03.003
2010;37(6):1361-1378.
60. Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y,
doi: 10.3892/ijo_00000788 El-Serag HB. Risk of hepatocellular cancer in HCV patients
treated with direct-acting antiviral agents. Gastroenterology.
50. Kum JJ, Khan ZA. Mechanisms of propranolol
action in infantile hemangioma. Dermatoendocrinol. 2017;153(4):996-1005.
2014;6(1):e979699. doi: 10.1053/j.gastro.2017.06.012

doi: 10.4161/19381980.2014.979699 61. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-
Ytter Y. Eradication of hepatitis C virus infection and the
51. Wu YL, van Hyfte G, Özbek U, et al. Outcomes of beta
blocker use in advanced hepatocellular carcinoma development of hepatocellular carcinoma: A meta-analysis
treated with immune checkpoint inhibitors. Front Oncol. of observational studies. Ann Intern Med. 2013;158(5_
2023;13:1128569. Part_1):329-337.
doi: 10.7326/0003-4819-158-5-201303050-00005
doi: 10.3389/fonc.2023.1128569
62. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate
52. Cheng HY, Lin HC, Lin HL, Uang YS, Keller JJ, Wang LH.
Association between nonselective beta-blocker use and of early tumor recurrence in patients with HCV-related
hepatocellular carcinoma in patients with chronic hepatitis B HCC undergoing interferon-free therapy. J Hepatol.
without cirrhosis and decompensation. Front Pharmacol. 2016;65(4):719-726.
2021;12:805318. doi: 10.1016/j.jhep.2016.04.008
doi: 10.3389/fphar.2021.805318 63. Cervello M, Montalto G. Cyclooxygenases in hepatocellular
carcinoma. World J Gastroenterol. 2006;12(32):5113.
53. Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-
term propranolol treatment on hepatocellular carcinoma doi: 10.3748/wjg.v12.i32.5113
incidence in patients with HCV-associated cirrhosis. Cancer 64. Bian W, Bian W, Li Q, Li Y. Aspirin in patients with
Prev Res (Phila). 2012;5(8):1007-1014.
viral hepatitis: Systematic review and meta-analysis
doi: 10.1158/1940-6207.CAPR-11-0450 of observational studies. J Gastrointest Cancer.
2024;55(2):638-651.
54. London WT, McGlynn KA. Can propranalol prevent
hepatocellular carcinoma? Cancer Prev Res (Phila). doi: 10.1007/s12029-024-01027-5
2012;5(8):989-991.
65. Zhou X, Zhang T, Sun Y, et al. Systematic review and
doi: 10.1158/1940-6207.CAPR-12-0247 meta-analysis: Association of aspirin with incidence of
hepatocellular carcinoma. Front Pharmacol. 2022;13:764854.
55. Kaewdech A, Sripongpun P. Challenges in the
discontinuation of chronic hepatitis B antiviral agents. doi: 10.3389/fphar.2022.764854
World J Hepatol. 2021;13(9):1042.
66. Mullen PJ, Yu R, Longo J, Archer MC, Penn LZ. The interplay
doi: 10.4254/wjh.v13.i9.1042 between cell signalling and the mevalonate pathway in
cancer. Nat Rev Cancer. 2016;16(11):718-731.
56. Lampertico P, Agarwal K, Berg T, et al. EASL 2017 Clinical
Practice Guidelines on the management of hepatitis B virus doi: 10.1038/nrc.2016.76

Volume 11 Issue 4 (2025) 28 doi: 10.36922/JCTR025080010